GDF15 and cancer: Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR‐associated protein 9 (Cas9)‐based genome editing have shown therapeutic potential for the treatment of various diseases such as cancers, blood disorders, and blindness.[15, 16, 17, 18, 19, 20] Compared to restoring antitumor immunity by current immunotherapies, such as adoptive immune cells or ICIs, direct suppression of GDF15 expression in tumor cells through genome editing is superior, including high specificity and persistent therapeutic benefits.